Streamlined Authorization Process for Cancer Treatment: A Model for Efficiency
A striking 95% of prior authorization requests for cancer treatment eventually receive approval, yet substantial delays are causing concern among both patients and healthcare providers.
According to a new CancerCare report, the authorization process significantly disrupts patient care, with nearly one-third of the surveyed 1,201 insured cancer patients experiencing diagnostic delays, while 40% endured postponed treatments. An emerging solution from Humana, Evolent Health, and the American Oncology Network (AON) is poised to address these inefficiencies through a streamlined authorization process, currently under trial at AON community clinics across eight states.
An Innovative Oncology Care Model
The new approach focuses on an oncology care model that allows clinics adhering to established treatment pathways to bypass the typical individual authorizations required for anticancer drug therapies. This model, currently implemented for Humana Medicare Advantage members, leverages Evolent Health’s expertise in providing clinical pathway infrastructure and performance reports.
The reform replaces traditional case-by-case approvals with a system evaluating adherence to evidence-based protocols, offering expedited access to therapies covered by these protocols. This includes a cutting-edge feature for immunotherapy monitoring, introducing automated reminders for necessary testing.
Addressing the Administrative Burden
The CancerCare report highlights the heavy administrative burden placed on patients, particularly those with employer-sponsored plans. It revealed that 87% of these patients encountered at least one prior authorization last year, with 63% managing the request process themselves. For some, this meant losing a full business week or more to resolve a single request.
- 87% of employer plan members dealt with at least one prior authorization
- 63% of employer plan members managed authorizations independently
- 12% lost a week or more due to a single authorization request
These statistics point to a systematic inefficiency in the authorization process, which often confirms suitable care practices but delays access due to administrative complexities.
Implications for Insurance Professionals
For insurance professionals, this development suggests a potential pivot in how prior authorizations are managed. The pathway-based model, although currently a part of Humana’s Medicare Advantage initiative, holds promise for broader applications. Evolent Health’s ongoing collaboration with Highmark indicates that commercial insurance sectors are keenly observing these developments.
With Highmark set to integrate this model in 2026 for medical and radiation oncology authorizations, and further rollouts to self-funded employer plans by 2027, the insurance landscape could witness a transformative shift.
The Future of Prior Authorizations
The moves by Humana and its partners underscore the necessity of reducing bureaucratic hurdles while maintaining care quality. The key question remains: will these innovations scale swiftly enough across insurance plans to alleviate the authorization burdens significantly? Industry watchfulness is warranted as advancements in such models continue to unfold.
“Community oncology centers are pivotal in cancer treatment. Our partnership introduces them to the latest evidence and quality interventions, easing treatment decisions and reducing approval friction that frustrates patients and providers.”
Stephen “Fred” Divers, AON’s Chief Medical Officer
The shift towards pathway adherence over individual approvals may mark a promising pathway towards more efficient and timely cancer care, with potential benefits that could reshape plan sponsor strategies and patient experiences alike.